[Gambas-user] Reduced activity

[Cristiano Guadagnino]

EMA (the European Medicines Agency) advises against the use of Ivermectin,
too.
And they have no economic interest in advising against it, quite to the
contrary.

https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin-prevention-treatment-covid-19-outside-randomised-clinical-trials

Bye
Cris
[image: cloudHQ] <https://www.free-email-tracker.com> Powered by
cloudHQ <https://www.free-email-tracker.com>

Il giorno sab 4 dic 2021 alle ore 19:38 T Lee Davidson <
t.lee.davidson at gmail.com> ha scritto:

> On 12/3/21 6:30 PM, Christof Thalhofer wrote:
> >
> [snip]
> > The RKI (Robert Koch Institut) in Germany states about Ivermectin
> (Translation):
>
> >> A meta-analysis of 14 randomised clinical trials (N=1678 patients,
> >> outpatients and hospitalised patients in separate analyses).
> >>
> >> * No effectiveness with respect to the clinical endpoints studied, such
> as
> >> 28-day mortality, clinical endpoints such as 28-day mortality, clinical
> >> worsening with the need for need for NIV/IMV* or O2 supplementation by
> day
> >> 28, viral clearance on day clearance on day 7 and no or low effect on
> >> clinical improvement by day 28. clinical improvement by day 28.
> >>
> >> * Low to very low level of evidence Several clinical trials with
> systemic
> >> and inhaled administration Not yet completed Reports of relevant
> toxicity
> >> in case of overdose.
> [snip]
>
> Well, the US National Institute of Health disagrees with the Robert Koch
> Institut. Perhaps you could have done a bit more research.
>
> Merck also put a statement against ivermectin. Hmm, I wonder why. Could it
> be because there is no profit in it for them? Is it
> possible that the RKI also has a conflict of interest?
>
> >
> > And doxycycline is a broad-spectrum antibiotic against bacteria with
> quite hard side effects:
> [snip]
> > Why should it help against viruses?
>
> Because it also has anti-viral properties. And, it has anti-inflammatory
> properties as well.
>
>
> On 12/3/21 6:49 PM, Jussi Lahtinen wrote:
>  > I will look later, if there is an explanation for the Indian numbers.
>  > However, ivermectin and doxycycline do not explain it.[snip]
>  > We do not eat them for a reason and it is not a conspiracy.
>
> I find it interesting that you, in your expert opinion, can conclusively
> state that ivermectin and doxycycline do not explain it
> when other experts indicate a different possibility. And, your blanket
> statement that, "We do not eat them for a reason," is
> factually incorrect as, obviously, some do; and, your reasoning is unsound.
>
>
>
> "Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin
> in the Prophylaxis and Treatment of COVID-19"
> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088823/]:
> "Meta-analyses based on 18 randomized controlled treatment trials of
> ivermectin in COVID-19 have found large, statistically
> significant reductions in mortality, time to clinical recovery, and time
> to viral clearance. Furthermore, results from numerous
> controlled prophylaxis trials report significantly reduced risks of
> contracting COVID-19 with the regular use of ivermectin.
> Finally, the many examples of ivermectin distribution campaigns leading to
> rapid population-wide decreases in morbidity and
> mortality indicate that an oral agent effective in all phases of COVID-19
> has been identified."
>
> "Ivermectin for Prevention and Treatment of COVID-19 Infection: A
> Systematic Review, Meta-analysis, and Trial Sequential
> Analysis to Inform Clinical Guidelines"
> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248252/]:
> "Moderate-certainty evidence finds that large reductions in COVID-19
> deaths are possible using ivermectin. Using ivermectin
> early in the clinical course may reduce numbers progressing to severe
> disease. The apparent safety and low cost suggest that
> ivermectin is likely to have a significant impact on the SARS-CoV-2
> pandemic globally."
>
> "Effects of Ivermectin in Patients With COVID-19: A Multicenter,
> Double-blind, Randomized, Controlled Clinical Trial"
> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101859/]:
> "A single dose of ivermectin was well-tolerated in symptomatic patients
> with COVID-19, and important clinical features of
> COVID-19 were improved with ivermectin use, including dyspnea, cough, and
> lymphopenia. Further studies with larger sample sizes,
> different drug dosages, dosing intervals and durations, especially in
> different stages of the disease, may be useful in
> understanding the potential clinical benefits ivermectin."
>
> "A five-day course of ivermectin for the treatment of COVID-19 may reduce
> the duration of illness"
> [https://pubmed.ncbi.nlm.nih.gov/33278625/]:
> "Ivermectin, a US Food and Drug Administration-approved anti-parasitic
> agent, was found to inhibit severe acute respiratory
> syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. [...]
> Virological clearance was earlier in the 5-day ivermectin
> treatment arm when compared to the placebo group [...] There were no
> severe adverse drug events recorded in the study. A 5-day
> course of ivermectin was found to be safe and effective in treating adult
> patients with mild COVID-19."
>
> "Ivermectin in COVID-19"
> [https://covid19criticalcare.com/ivermectin-in-covid-19/]:
> "We regard ivermectin as a core medication in the prevention and treatment
> of COVID-19."
>
> "Doxycycline as a potential partner of COVID-19 therapies"
> [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298522/]:
> "Because patients with COVID-19 are in need of both antiviral and
> anti-inflammatory treatment as well as protection against lung
> damage, studies of proposed combination therapy is warranted. As
> doxycycline is inexpensive and widely available, has a safe
> tolerability profile, and is an attractive option for the treatment of
> COVID-19 as well as potentially alleviating the lung
> sequelae and also providing coverage against atypical bacterial pneumonia
> such as Mycoplasma pneumoniae and Legionella
> pneumophilia."
>
> "Doxycycline treatment of high-risk COVID-19-positive patients with
> comorbid pulmonary disease"
> [https://pubmed.ncbi.nlm.nih.gov/32873175/]:
> "Tetracycline and its derivatives (e.g. doxycycline and minocycline) are
> nontraditional antibiotics with a well-established
> safety profile, potential efficacy against viral pathogens such as dengue
> fever and chikungunya, and may regulate pathways
> important in initial infection, replication, and systemic response to
> SARS-CoV-2. We present a series of four high-risk,
> symptomatic, COVID-19+ patients, with known pulmonary disease, treated
> with doxycycline with subsequent rapid clinical
> improvement. No safety issues were noted with use of doxycycline."
>
>
> --
> Lee
>
> ----[ http://gambaswiki.org/wiki/doc/netiquette ]----
>
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.gambas-basic.org/pipermail/user/attachments/20211204/48fc0f16/attachment-0001.htm>